topSkip to main content

Menu, Secondary

Menu Trigger

Menu

National Institutes of Health

Biomedical research funded by the National Institutes of Health (NIH) and performed at research universities helps assure U.S. leadership in the life sciences revolution of the 21st Century. Putting NIH on a sustained pathway to restore its purchasing power after a decade worth of loss to inflation and budget cuts is critical to sustaining the extraordinary progress in the improvement of human health of the past decades. Investment in NIH will continue to create jobs and strengthen the workforce, improve the lives—and quality of life—of millions of current and future patients, and help assure continuing U.S. economic and national security.

Sustained investment in biotechnology and genomics is crucial to the development of novel therapies for diseases, including: cancer, Alzheimer's, autism, and diabetes. The NIH also responds rapidly to public health emergencies and in support of biodefense, such as in the case of Ebola, Zika, and COVID-19.

 

AAU joined 4 other associations in sending a letter to Dr. Bhattacharya at the NIH to reinstate the grants that have been "terminated under agency directives found by a federal court to be unlawful."
An administration order to the NIH to cease critical appropriated funding for ongoing and new clinical trials of treatments and cures for American patients who need it most would end ongoing life-saving cancer research, desperately needed Alzheimer's research, and diabetes research, among others.
A permanent 10% reduction in federal funding for the National Institutes of Health would lead to fewer drugs coming to market, finds a new analysis by the Congressional Budget Office.
President Trump’s FY26 budget proposal, if adopted, would destroy America’s longstanding role as the global leader in science and innovation – along with the countless health, security, and economic benefits that flow from that leadership.
AAU has issued a statement regarding provisions slashing research funding in the newly released FY26 Presidential Budget Request.
Every $1 spent by the National Institutes of Health in research funding in FY24 generated $2.56 of economic activity, according to a new report by United for Medical Research.
AAU joined APLU, ARL, and COGR to submit a letter to the NIH Office of Science Policy expressing their strong support for NIH's vision for standardizing metadata and PIDs.
This is a legal filing contesting the unlawful and damaging decree by the administration to cap F&A reimbursement rates to a 15% for all NIH research.
AAU, ACE, and APLU have jointly filed suit in U.S. District Court in Massachusetts, along with a number of impacted research university co-plaintiffs, seeking to halt the NIH's proposed cut to life-saving medical research.
This page will be updated regularly to provide new information as it becomes available regarding the AAU-ACE-APLU lawsuit contesting the National Institutes of Health cutting reimbursement rates to 15%.